Person: KARATOPRAK, CUMALİ
18 results
Search Results
Now showing 1 - 10 of 18
Publication Open Access Effect of transfusion of washed red blood cells on serum potassium level in hemodialysis patients(2017-01-01) DEMIRTUNC, Refik; OZENSOY, Ugur; CETINKAYA, Fuat; KAYATAS, Kadir; USTUN, Emel; Kazancioglu, RÜMEYZA; KARATOPRAK, CUMALİ; KARATOPRAK, CUMALİ; KAZANCIOĞLU, RÜMEYZABackground/aim: This study aimed to compare washed red blood cell (WRBC) transfusion versus nonwashed RBC (NWRBC) transfusion in terms of posttransfusion potassium levels in dialysis patients on a day when the patient did not receive dialysis. Materials and methods: The patients were randomly assigned into two groups, i.e. those receiving WRBCs (n = 21) and those receiving NWRBCs (n = 17). Both groups received one unit of RBCs. Serum potassium and sodium levels were measured before and at the 1st, 2nd, 3rd, 4th, and 6th hours after transfusion. Results: In the WRBC group, the changes in the serum potassium levels at the 3rd, 4th, and 6th hours after transfusion were significant compared with pretransfusion levels. In the serum potassium levels mean decreases by 0.38 ± 0.57 mEq/L at the 3rd hour (P = 0.006), by 0.32 ± 0.47 mEq/L at the 4th hour (P = 0.005), and by 0.32 ± 0.51 mEq/L at the 6th hour (P = 0.009) after transfusion were significant compared with the pretransfusion levels. Conclusion: Although nonwashed RBC transfusion does not change serum potassium levels, washed RBC transfusion significantly reduces serum potassium levels. Washed RBC transfusion is considered to be safer in hemodialysis patients with hyperkalemia and anemia.Publication Open Access Assessment of serum endocan levels in patients with beta-thalassemia minor(2022-02-01T00:00:00Z) Zorlu, Mehmet; Ozer, Ömer Faruk; Karatoprak, Cumali; Kıskaç, Muharrem; Çakırca, Mustafa; ZORLU, MEHMET; ÖZER, ÖMER FARUK; KARATOPRAK, CUMALİObjective: Beta-thalassemia minor is a blood disease caused by a hereditary decrease in beta-globin synthesis, frequently leading to hypochromic microcytic anemia. Formerly called endothelial cell-specific molecule 1, endocan is a proteoglycan released by vascular endothelial cells in many organs. Our aim was to investigate the relationship between the beta-thalassemia minor patients and the healthy control group in terms of serum endocan level. Methods: The study was performed in a total of 80 subjects. They were divided into two groups, the beta-thalassemia minor group (n=40) and the healthy control group (n=40). Serum endocan levels, age, sex, body mass index value, and tobacco use data of these groups were compared. Results: No statistically significant difference was detected between the two groups in terms of age, sex, and body mass index values (p>0.05). Endocan levels were measured to be 206.85±88.1 pg/mL in the beta-thalassemia minor group and 236.1±162.8 pg/mL in the control group with no significant difference between the groups in terms of serum endocan levels (p>0.05). Conclusions: In our study, there was no change in endocan level in beta-thalassemia minor. This might be because serum endocan levels are affected by multi-factorial reasons. Serum endocan levels may be altered secondarily to decreased beta-globin chain, increased sympathetic activity due to anemia, or platelet dysfunction induced by oxidative stress in beta-thalassemia minor. Further multicenter studies involving more patients are necessary to demonstrate this.Publication Open Access CD40 ligand and P-selectin in heterozygous Beta-thalassemia(2016-06-01) CIKRIKCIOGLU, Mehmet Ali; SOYTAS, Rabia Bag; KILIC, Elif; Toprak, Aybala Erek; Karatoprak, CUMALİ; Zorlu, MEHMET; Kiskac, MUHARREM; EMEGIL, Sebnem; Cetin, GÜVEN; Dogan, ELİF ECE; SEKIN, Yahya; HAMDARD, Jamshid; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇETİN, GÜVEN; DOĞAN, ELİF ECE; KARATOPRAK, CUMALİObjective: To investigate platelet functions and measure soluble CD40 ligand, soluble P-selectin, beta-thromboglobulin and platelet factor 4 levels in the blood of heterozygous beta thalassemia patients. Methods: The cross-sectional case-control study was conducted at Bezmialem Vakif University, Istanbul, Turkey, between September 2013 and April 2014, and comprised heterozygous beta thalassemia patients who were compared with 41 gender-, age- and body mass index-matched controls for platelet function markers. The two groups were also compared for co-morbidities, smoking, and regular medications. Results: Of the 78(78.78) subjects, 50(64%) were women and 28(36%) men with an overall mean age of 39.4±12.7 years (range: 18-79 years). The mean body mass index was 26.3±4.2. The heterozygous beta thalassemia group included 37(47%) subjects [24(65%) females; 13(35%) males] while the control group had 41(53%) [26(63%) females; 15(37%) males]. Soluble CD40 ligand and soluble P-selectin were lower in the heterozygous beta thalassemia group (p=0.009; p=0.010). Beta-thromboglobulin and platelet factor 4 levels were comparable between the groups (p=0.497; p=0.507.). Conclusions: Some platelet functions may be reduced in heterozygous beta thalassemia patients, which may be related to their lower incidence of cerebral and cardiac ischaemic events.Publication Open Access Serum endocan levels in women with restless legs syndrome.(2015-11-19) CELIK, K; ÇıKRıKÇıOĞLU, MA; HALAC, G; KILIC, ERDEM; AYHAN, S; OZARAS, N; Karatoprak, CUMALİ; YILDIZ, KEMALETTİN; YILDIZ, RS; ZORLU, MEHMET; CAKIRCA, MUSTAFA; KıSKAÇ, MUHARREM; KILIÇ, ERDEM; YILDIZ, KEMALETTİN; ZORLU, MEHMET; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREMBackground: Endocan is a recently introduced marker of endothelial dysfunction. The objective of this study was to compare serum endocan levels in patients with restless legs syndrome (RLS) and control subjects in order to elucidate whether RLS is associated with endothelial dysfunction. Methods: A total of 31 drug naïve female patients with RLS and 31 age- and BMI-matched women were included in the study. Patients with pathological or physiological conditions or with a history of medication use that could potentially influence endothelial functions were excluded, as well as those with alcohol or drug abuse history. The two groups were compared with routine blood tests and serum endocan levels. Results: Patients with RLS had lower serum endocan levels than the controls (P=0.037). There was a negative bivariate correlation between RLS severity score and serum endocan levels (r=-0.406, P=0.023). While white blood cell count was significantly higher in RLS group, 25-hydroxy vitamin D3, vitamin B12, transferrin saturation rate, and HDL-cholesterol were significantly lower. Creatininemia and diastolic blood pressure were also marginally insignificantly lower in RLS group. Due to the presence of differences between two groups in these variables, a linear regression analysis was performed that showed a positive association between endocan and creatininemia (β=0.310, P=0.022), and a negative association between endocan and RLS (β=-0.502, P,0.001). Conclusion: The results of this study seem to suggest that patients with RLS may have better endothelial functions when compared with the general population and that these patients may be better protected against atherosclerosisPublication Open Access Association of calcium channel blocker use with lower hemoglobin levels in chronic kidney disease(2013-09-01) Karatoprak, CUMALİ; CIKRIKCIOGLU, M. A.; Cakirca, MUSTAFA; Kiskac, MUHARREM; Zorlu, MEHMET; Cetin, GÜVEN; YILDIZ, KEMALETTİN; ERKOC, R.; ALAY, M.; Erkal, S.; Erkal, S. N.; DOGAN, S.; Kazancioglu, RÜMEYZA; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇETİN, GÜVEN; YILDIZ, KEMALETTİN; KAZANCIOĞLU, RÜMEYZAAim: To search whether calcium channel blockers (CCBs) are associated with lower hemoglobin levels in chronic kidney disease (CKD) patients who are not on renal replacement therapy (RRT), vitamin D and anti-anemic treatment. Patients and methods: CKD patients were classified into two groups. Patients on CCBs treatment (103 patients) and patients not using CCBs (104 patients) were compared cross-sectionally regarding clinical findings, complete blood count (CBC), biochemistry and regular medication use. Patients with polycystic kidney disease, comorbidities that could influence CBC other than iron deficiency of obscure origin, patients receiving RRT, erythropoietin (EPO), vitamin D, phosphate binders and drugs that could influence CBC were excluded. Under dependent variable of CCB use, all significantly different independent variables were subjected to multivariate binary logistic regression analysis (MBLRA). Results: Lower hemoglobin, lower bilirubinemia, higher serum EPO, higher systolic blood pressure were observed in CCB users. Two groups were similar concerning age, gender, BMI, CKD etiology, CKD stage, pretibial edema prevalence, cardiothoracic index, diastolic blood pressure, corrected reticulocyte count, BUN, creatinine, eGFR, proBNP, parathormone, alkaline phosphatase, phosphorous, corrected calcemia, sCRP, relative EPO deficiency and prevalence of relative EPO deficient patients. Groups were comparable regarding comorbidities, types and usage frequencies of all antihypertensive medications other than CCBs. Higher systolic blood pressure and lower hemoglobin were significantly associated with CCB use after MBLRA. Conclusions: Hemoglobin was significantly lower in CCB users compared to non-users, among CKD patients who did not receive RRT, EPO, phosphate binders, vitamin D, iron, vitamin B12 and folic acid.Publication Open Access Report of a Case of Signet Ring Carcinoma Presenting as Gastric Mucosal Thickening: A Diagnostic Dilemma(2021-01-01T00:00:00Z) Karatoprak, Cumali; Akçakaya, Adem; Şentürk, Hakan; Çoban, Ganime; Şahin, Nurhan; Türk, Hacı Mehmet; KARATOPRAK, CUMALİ; AKÇAKAYA, ADEM; ŞENTÜRK, HAKAN; ÇOBAN, GANİME; ŞAHİN, NURHAN; TÜRK, HACI MEHMETThe number of cancer cases has been increasing worldwide. Early diagnosis and tumor resection remain as the most effective treatments for gastric cancer. However, early diagnosis is not always possible as it is frequently not possible to make treatment decisions without pathologic diagnosis in patients with clinically suspected cancer. This causes delays in diagnosing cancer. We presented a 58 years old woman with gastric signet ring cell carcinoma that could not be diagnosed despite using four different methods of stomach biopsies. We aimed to emphasize that despite the use of advanced methods, if clinical cancer in non-diagnosed cases is suspected, we should be more aggressive for early diagnosis.Publication Open Access Elevated beta-thromboglobulin and mean platelet volume levels may show persistent platelet activation in systemic lupus erythematosus patients.(2018-09-01) Karatoprak, CUMALİ; UYAR, S; ABANONU, Gul Babacan; PEHLEVAN, SM; MENGÜÇ, MU; DAŞKIN, A; DOLU, S; DEMIRTUNÇ, R; KARATOPRAK, CUMALİBackground. Patients with systemic lupus erythematosus (SLE) have anincreased risk of thrombotic events. Platelets become more active and they enlarge torelease proteins from alpha granules for aggregation during the plaque formation period. Beta-thromboglobulin isone of the proteins released from alpha-granules when platelets are activated and used as a marker ofplatelet activation invivo. Objectives. The aim of this study was to evaluate the plasma levels of beta-thromoglobulin and mean platelet volume as markers of the presence ofplatelet activation insystemic lupus erythematosus patients compared with healthy controls. Material and methods. Thirty-seven SLE patients with a mean disease duration of4.96years and without any organ involvement as well as 30 healthy volunteers were included in the study. All patients were inremission ofSLE. Results. Themean beta-thromboglobulin level was 97.36±55.8ng/mL inthe SLE group and 72.67±33.5ng/mL inthe control group (p = 0.029). The mean platelet volume level was 8.27 ±1.68 fL inthe SLE group and 9.16 ±1.52 fL (p = 0.031) inthe controls. Conclusions. Elevated beta-thromboglobulin levels in systemic lupus erythematosus patients may be associated with platelet activation inthe early stages ofdisease, whereas lower mean platelet volume levels inthe same population may be due tothe effects ofhydroxychloroquine and the inactivity ofSLE.Publication Open Access The relationship between the atherosclerotic cardiovascular disease risk score used in the prediction of cardiovascular disease risk and endocan.(2019-05-01T00:00:00Z) Cakirca, M; Tunc, M; Zorlu, M; Dae, SA; Kiskac, M; Karatoprak, CUMALİ; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; TUNÇ, MUHAMMED; KARATOPRAK, CUMALİObjective: To date, there have been no studies investigating whether or not there is a correlation between the serum endocan level and the atherosclerotic cardiovascular disease (ASCVD) risk score that is frequently used in the determination of the risk of cardiovascular disease. If a single parameter such as endocan can provide reliable results which could be used in the prediction of the cardiovascular disease risk, the workload of the clinician would be lightened. The aim of this study was to investigate whether or not there is an association between the serum endocan level and the ASVCD risk score. Materials and methods: This prospective, cross-sectional study included individuals age 40-79 years with risk factors calculated using the ASVCD score and individuals without any of those risk factors. In accordance with ASCVD risk calculation, each participant was questioned with respect to age, gender, height, weight, and lifestyle habits such as smoking, diseases, and medications. Systolic blood pressure, diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and serum endocan levels were measured and recorded. The serum endocan levels and ASCVD scores were compared. Results: The study included 205 individuals, comprising 92 (44.9%) males and 113 (55.1%) females with a mean age of 50.7 ± 7.6 years. The 10-year atherosclerosis risk was determined as mean 6.32% ± 5.9% (range, 0.3%-27.3%). The mean serum endocan level was calculated as 1109.6 ± 1479.7 ng/mL. As the ASCVD risk score increased, no increase was detected in the serum endocan level. Conclusion: The results of the study suggested that the serum endocan level is not suitable for use in place of the ASCVD risk score as a predictor of cardiovascular disease risk.Publication Open Access Severe hypercalcemia due to teriparatide(2012-03-01) KAYATAS, K; Karatoprak, CUMALİ; KILICASLAN, H; YOLBAS, S; YAZIMCI, NA; GÜMÜSKEMER, T; DEMIRTUNÇ, R; KARATOPRAK, CUMALİPublication Open Access GAS6 intron 8 c.834 + 7G > A gene polymorphism in diabetic nephropathy.(2015-06-01) ERKOÇ, R; ÇıKRıKÇıOĞLU, MA; AINTAB, E; TOPRAK, ALİ; KILIC, U; GOK, O; CETIN, AI; ZORLU, MEHMET; KıSKAÇ, MUHARREM; CAKIRCA, MUSTAFA; Karatoprak, CUMALİ; ISEN, HC; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİBackground - Aim: In animal experiments, growth arrest-specific 6 (Gas6) protein plays a key role in the development of mesangial cell and glomerular hypertrophy in the early phase of diabetic nephropathy, and diabetic nephropathy is prevented by warfarin-induced inhibition of GAS6 protein. It was shown that GAS6 intron 8 c.834+7G>A polymorphism is protective against type 2 diabetes mellitus, and AA genotype is associated with higher blood levels of GAS6 protein. Our aim is to investigate whether this polymorphism is a risk factor for diabetic nephropathy in type 2 diabetes mellitus. Method: Eighty-seven patients with diabetic nephropathy were compared with 66 non-diabetic controls in terms of GAS6 intron 8 c.834+7G>A polymorphism. Patients with history of stroke, ischemic heart disease were excluded. Each patient was examined by the ophthalmologist to determine diabetic retinopathy. Results: Frequency of GG, GA and AA genotypes are similar in diabetic nephropathy and control groups according to GAS6 intron 8 c.834+7G>A polymorphism (p = 0.837). Rate of diabetic retinopathy was 54.02%. In the subgroup analysis, GA genotype was significantly more frequent than GG genotype in patients with diabetic retinopathy when compared to without diabetic retinopathy (p = 0.010). Conclusion: In our study, GAS6 intron 8 c.834+7G>A polymorphism was not associated with diabetic nephropathy in type 2 diabetes mellitus. However, heterozygous state of this polymorphism may be a risk factor for diabetic retinopathy in patients with diabetic nephropathy.